Stryker down despite boosting 2025 outlook and Q3 beats

 

• Stryker (SYK) is down ~3% in after-hours trading Thursday despite raising its 2025 EPS outlook and having a double beat in its Q3 results.
• Non-GAAP EPS is now seen at $13.50-$13.60, up from $13.40-$13.60 prior. Consensus is $13.49.
• Organic sales growth is now expected to rise 9.8%-10.2% compared to 2024, up from 9.5%-10%.
• Sales in Stryker's largest business, MedSurg and Neurotechnology, rose 14.4% to ~$3.8B. In the Orthopedics segment, revenue rose 12.5% to ~$2.2B.
• Non-GAAP EPS in Q3 of $3.19 compares to $2.87 in the year-ago period.
• Stryker had cash and cash equivalents of ~$3.3B at the end of the quarter (Sept. 30) compared to ~$3.7B on Dec. 31, 2024.

https://www.msn.com/en-us/money/companies/stryker-down-despite-boosting-2025-outlook-and-q3-beats/ar-AA1PwIcw